Amgen submits erenumab BLA, hoping to stop migraine misery

Biotech giant Amgen (Nasdaq: AMGN) has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for erenumab, a treatment designed to prevent migraine by blocking the calcitonin gene-related peptide (CGRP) receptor.

The US biotech major, which plans to co-commercialize erenumab with Swiss pharma giant Novartis (NOVN: VX) in the US market, has included in the BLA data from pivotal studies in patients with episodic and chronic migraine.

Sean Harper, executive vice president of research and development at Amgen, said: “People with migraine lose a substantial part of their lives enduring or managing the disease, which takes time away from their loved ones, social activities and workplace responsibilities.